Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adverum Biotechnologies

4.57
+0.07101.58%
Volume:23.19K
Turnover:105.94K
Market Cap:95.09M
PE:-0.83
High:4.67
Open:4.51
Low:4.51
Close:4.50
Loading ...

Adverum Biotechnologies Inc expected to post a loss of $1.36 a share - Earnings Preview

Reuters
·
Yesterday

Adverum Biotechnologies initiates ARTEMIS study

TIPRANKS
·
04 Mar

Adverum Biotechnologies Initiates Artemis Phase 3 Study Evaluating Ixo-Vec for Wet Amd

THOMSON REUTERS
·
04 Mar

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

GlobeNewswire
·
04 Mar

Major Investment Alert: Adverum Biotechnologies Sees Significant Share Purchase!

TIPRANKS
·
01 Mar

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
01 Mar

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

GlobeNewswire
·
25 Feb

3 US Penny Stocks With Market Caps Below $400M

Simply Wall St.
·
19 Feb

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Dec 2024

Adverum Biotechnologies management to meet virtually with Truist

TIPRANKS
·
07 Dec 2024

Adverum Biotechnologies price target lowered to $16 from $20 at Mizuho

TIPRANKS
·
23 Nov 2024

Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained

MT Newswires Live
·
23 Nov 2024

BRIEF-Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule

Reuters
·
21 Nov 2024

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Nov 2024

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Nov 2024

Truist Financial Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)

TIPRANKS
·
19 Nov 2024